NasdaqGM - Nasdaq Real Time Price USD

Affimed N.V. (AFMD)

5.24

-0.02

(-0.38%)

At close: May 14 at 4:00 PM EDT

5.40

+0.16

(+3.05%)

After hours: May 14 at 6:33 PM EDT

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse modelAFM28 led to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells in a newly engineered ex vivo bone marrow niche model MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa

GlobeNewswire 12 hours ago

AFMD
-0.38%
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 14 hours ago

AFMD
-0.38%
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade

The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 20 days ago

AFMD
-0.38%
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2

GlobeNewswire 20 days ago

AFMD
-0.38%
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 27 days ago

AFMD
-0.38%
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?

The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

AFMD
-0.38%
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript

Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript March 28, 2024 Affimed N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone, and welcome to Affimed’s Fourth Quarter and Full Year 2023 Earnings and Corporate Update Call. At […]

Insider Monkey last month

AFMD
-0.38%
Affimed Reports 2023 Financial Results and Operational Progress

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily pretreated patients who were evaluated. Mature progression free survival (PFS) data from the 15 EGFR-wildtype NSCLC patients and initial efficacy data from the EGFR-mutant NSCLC cohorts are expected in Q2 2024.A

GlobeNewswire last month

AFMD
-0.38%
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2023 results and corporate update on March 28, 2024. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be a

GlobeNewswire last month

AFMD
-0.38%
Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know

Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

AFMD
-0.38%
7 of the Best Speculative Stocks You Can Snag for Less Than $1

I’m about to drop a truth bomb about speculative stocks under $1. Back when I was a freshman in college, the on-campus security officer had this to say: “Tijuana? You don’t wanna.” Subsequently, the crowd erupted in laughter but the officer got his point across. Yes, Tijuana is an exciting and vibrant city, no doubt about it. However, people – especially young underage college students – can get carried away. That’s the reality behind speculative stocks under $1. It’s like Tijuana, where the sam

InvestorPlace 2 months ago

AFMD
-0.38%
AKTS

NAK
Affimed Announces 1-for-10 Reverse Stock Split

MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the Company, with prior approval of the Company’s supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 (“Common Shares”) per share. The reverse stock split is expected to be

GlobeNewswire 2 months ago

AFMD
-0.38%
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohortFollow-up shows three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scanStudy to be expanded to a total of 40 EGFRwt NSCLC patientsEnrollment in the EGFR-mutant (mut) NSCLC cohort is ongoingData from both the EGFRwt and EGFRmut cohorts expected in H1 2024 MAN

GlobeNewswire 4 months ago

AFMD
-0.38%
Affimed Announces Leadership Change and Organizational Restructuring

Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025Go forward organization will focus on advancing clinical programsCompany confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024 MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (the "Company" or "Affimed"), a clinical-stage immuno-oncology company com

GlobeNewswire 4 months ago

AFMD
-0.38%
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines. Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6 million, consisting of $5 millio

GlobeNewswire 4 months ago

AFMD
-0.38%
3 Penny Stocks That Are Too Compelling to Ignore

While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors shy away from the sector because of the extreme risks involved. It’s not just that investing in this arena is dangerous to your financial standing; rather, the ecosystem can be very addictive. Nevertheless, without fail, people continue to request ideas regarding top penny stocks. Since it doesn’t make a whol

InvestorPlace 4 months ago

AFMD
-0.38%
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort Responses observed in 4 of 15 patients, including 1 confirmed partial response (PR), 1 unconfirmed complete response (CR) awaiting confirmation, 2 unconfirmed PRs awaiting confirmation; an additional 7 of 15 patients exhibiting stable disease (SD) leading to a disease control rate of 73%Tumor shrinkage observed in 7 of 15 (47%

GlobeNewswire 5 months ago

AFMD
-0.38%
$Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)$
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR) was 97% and the complete response (CR) rate was 78%In this cohort median EFS was 9.8 months with 84% patients alive at 12 months, and median duration of response (DoR) was 8.8 monthsPatients were heavily pretreated (median of 7 prior lines), all had previously received CPIs and BV, and were refractory to their most recent line of therapyPatie

GlobeNewswire 5 months ago

AFMD
-0.38%
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203Review clinical data for AFM24 in solid tumorsConference call/webcast on Monday, December 11, 2023 at 1:30 p.m. PST / 4:30 p.m. EST / 22:30 CET MANNHEIM, Germany, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability

GlobeNewswire 5 months ago

AFMD
-0.38%
Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good day, everyone, and welcome to Affimed N.V. Third Quarter 2023 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there’ll be a question-and-answer session. [Operator Instructions]. Please be advised that today’s […]

Insider Monkey 5 months ago

AFMD
-0.38%

Performance Overview

Return	AFMD	S&P 500
YTD	-16.16%	+10.00%
1-Year	-39.70%	+27.22%
3-Year	-94.09%	+27.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Affimed N.V. (AFMD)

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates

Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?

Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript

Affimed Reports 2023 Financial Results and Operational Progress

Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024

Affimed N.V. (AFMD) Upgraded to Buy: Here's What You Should Know

7 of the Best Speculative Stocks You Can Snag for Less Than $1

Affimed Announces 1-for-10 Reverse Stock Split

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Affimed Announces Leadership Change and Organizational Restructuring

Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck

3 Penny Stocks That Are Too Compelling to Ignore

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Affimed N.V. (NASDAQ:AFMD) Q3 2023 Earnings Call Transcript

Performance Overview